
{
  "documentMetadata": {
    "title": "Erythema Migrans, Lyme Disease, Early",
    "lastUpdated": "2024-04-12",
    "sourceFile": "syndromes/skin_and_soft_tissues/Erythema migrans, Lyme Disease, Early.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Erythema migrans skin lesions (70-80% of patients). Early manifestation of Lyme disease, a spirochetal tick borne illness. See Lyme Disease, Overview for other stages and syndromes.",
        "Most common in the US between April and September in the Northeast, Middle Atlantic and North Central states. Rarely in Northern California and Oregon.",
        "Skin lesions are usually homogeneous, not target-like, see Ann Intern Med 136:421, 2002."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Diagnosis"
    },
    {
      "type": "list",
      "items": [
        "For details on diagnostic methods see: Lyme Disease, Diagnosis and Emerging Infect Dis 22:1169, 2016.",
        "Antibody tests often negative in early Lyme Disease; takes 4-6 weeks to develop antibody.",
        "When one or more typical skin lesion of erythema migrans is present, no diagnostic testing is recommended"
      ]
    },
    {
        "type": "nestedContent",
        "content": [
            {
                "type": "paragraph",
                "text": "Antibody testing indicated if:"
            },
            {
                "type": "list",
                "items": [
                    "Exposure to endemic area",
                    "Risk factor(s) for tick exposure",
                    "Signs of late disease (e.g., meningitis, nerve palsy, carditis, arthritis)"
                ]
            }
        ]
    },
    {
        "type": "nestedContent",
        "content": [
            {
                "type": "paragraph",
                "text": "Two-step testing of blood for specific antibodies"
            },
            {
                "type": "list",
                "items": [
                    "Enzyme immunoassay (EIA) or immunofluorescence assay (IFA) followed by Western Blot (WB): if EIA or IFA is negative, no further testing is recommended."
                ]
            }
        ]
    },
    {
        "type": "nestedContent",
        "content": [
            {
                "type": "paragraph",
                "text": "Western blot diagnostic criteria (to be performed if EIA or IFA is positive):"
            },
            {
                "type": "list",
                "items": [
                    "IgM antibody - Need 2 of 3 positive of kilodaltons (KD): 23, 39, 41",
                    "IgG antibody - Need 5 of 10 positive of KD: 18, 21, 28, 30, 39, 41, 45, 58, 66, 93"
                ]
            }
        ]
    },
    {
        "type": "list",
        "items": [
            "Sensitivity of testing for IgM or IgG antibody is suboptimal during the first 2 weeks of disease"
        ]
    },
    {
        "type": "nestedContent",
        "content": [
            {
                "type": "paragraph",
                "text": "Second generation antibody assay: Antibody to C6; in high prevalence areas, need to look for co-infection with Babesia microti and/or Anaplasma phagocytophilum"
            },
            {
                "type": "list",
                "items": [
                    "Less specific than full two-step test described above but, positive earlier in the infection",
                    "Helpful in discriminating true vs false positive IgM immunoblot assay",
                    "Better at detection of European Lyme disease due to B. garinii or B. afzellii",
                    "Not yet part of official guidelines. References: Clin Infect Dis 57:333, 2013; Clin Infect Dis 57:341, 2013."
                ]
            }
        ]
    },
    {
        "type": "list",
        "items": [
            "May be able to detect organism by PCR on CSF or joint fluid.",
            "Babesia diagnosis: visible on blood smears, serologic testing, or PCR",
            "Anaplasma diagnosis: sensitivity of smears is poor, diagnosis by serology or PCR."
        ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Borrelia burgdorferi spirochetes are among 5 Borrelia spp isolated from humans suspected of tick-borne illness in US (Clin Infect Dis 66: 1864, 2018)",
        "Borrelia miyamotoi less common than B burgdorferi in surveys from New England and New York (Emerg Infect Dis 20: 1183, 2014)",
        "Borrelia mayonii identified in Minnesota, Wisconsin, North Dakota; high spirochetemia, diffuse rash (Lancet Infect Dis 16: 556, 2016)",
        "There are 5 or more species known to cause disease in Europe. Clinical symptoms vary.",
        "Ixodes deer tick is the vector. Image is nymphal stage tick."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "See Comments regarding treatment considerations if dual infection, e.g., Lyme, anaplasma, babesia"
      ]
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "appliesTo": {
          "description": "Adult"
        },
        "components": [
          { "drug": "Doxycycline", "dose": "100 mg", "route": "po", "frequency": "bid", "durationDetail": { "fixedDuration": "10 days" } },
          { "drug": "Amoxicillin", "dose": "500 mg", "route": "po", "frequency": "tid", "durationDetail": { "fixedDuration": "14 days" } },
          { "drug": "Cefuroxime axetil", "dose": "500 mg", "route": "po", "frequency": "bid", "durationDetail": { "fixedDuration": "14 days" } }
        ],
        "notes": "Cephalexin is NOT effective"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "appliesTo": {
          "description": "Pediatric"
        },
        "components": [
          { "drug": "Doxycycline", "dose": "4.4 mg/kg/day", "route": "po", "frequency": "divided q12h", "notes": "max of 200 mg per day. Considered safe regardless of age for up to 21 days (AAP Red Book 2018, Section 4; J Pediatr 166:1246, 2015)"},
          { "drug": "Amoxicillin", "dose": "50 mg/kg/day", "route": "po", "frequency": "in 3 divided doses", "durationDetail": { "fixedDuration": "14-21 days" }, "connector": "or" },
          { "drug": "Cefuroxime axetil", "dose": "30 mg/kg/day", "route": "po", "frequency": "in 2 divided doses", "durationDetail": { "fixedDuration": "14-21 days" }, "notes": "Cefuroxime suspension not available in the US, may be available in other markets." },
          { "drug": "Azithromycin", "dose": "10 mg/kg per day", "route": "po", "durationDetail": { "fixedDuration": "7-10 days" } }
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          { "drug": "Azithromycin", "dose": "500 mg", "route": "po", "frequency": "once daily", "durationDetail": { "fixedDuration": "7 days" } }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "appliesTo": {
            "description": "Pregnancy"
        },
        "components": [
          { "drug": "Amoxicillin", "dose": "500 mg", "route": "po", "frequency": "tid", "durationDetail": { "fixedDuration": "14 days" } }
        ],
        "notes": "avoid Doxycycline in pregnancy"
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Dual infection:",
        "Doxycycline would also treat anaplasma (but not babesia) if dual infection present",
        "Amoxicillin and Cefuroxime axetil would not be effective against concomitant Babesiosis or Granulocytic anaplasmosis.",
        "2020 Clinical practice guidelines (Neurology 96:262, 2021) and (Clin Infect Dis 72:e1-e48, 2021)",
        "Review in JAMA 315:1767 & 2461, 2016.",
        "High rate of clinical failure reported with Azithromycin and Erythromycin, Drugs 57:157, 1999."
      ]
    }
  ]
}
